following an abbreviated submission:
dolutegravir, abacavir plus lamivudine tablets (Triumeq®) are accepted for use within NHS Scotland.
Indication under review: for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.
In patients for whom this combination is appropriate, it offers a single tablet at a lower cost per dose compared with the individual components.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of (Triumeq®). This advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice72KB (PDF)
- Medicine name:
- dolutegravir, abacavir, lamivudine (Triumeq)
- SMC ID:
- for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.
- Pharmaceutical company
- ViiV Healthcare/GSK
- BNF chapter
- Submission type
- Date advice published
- 08 December 2014